Objective: To evaluate association of visit-to-visit HbA1c variability and absolute changes in HbA1c with poor glycemic control in patients with diabetes.
Introduction
Diabetes is one of the most common chronic diseases as well as a leading cause of death and disability worldwide [1, 2] . Since the Diabetes Control and Complication Trial and the United Kingdom Prospective Diabetes Study demonstrated that excellent glycemic control reduces microvascular complications in types 1 and 2 diabetes mellitus, respectively [3, 4] . Glycated hemoglobin A1c (HbA1c) level has become an increasingly important measure of glycemic control. Glycemic controlis one of the important strategies for the management of diabetes to prevent complications and to reduce the overall disease care cost as regarded by the American Diabetes Association [5] . Despite the strong consensus that excellent glycemic control improves diabetes outcomes and reduces health care costs [6] , there are a lot of patients with diabetes who still have poor glycemic control [7, 8] . The Center for Medicare and Medicaid Services (CMS) uses its Medicare STAR program to monitor and reward the quality of care in health plans with Medicare Advantage enrollees, and provides substantial incentives to health plans that perform well on its Medicare STAR metrics [9] . One among the nine tripleweighted metrics is Diabetes Care-Blood Sugar Controlled (i.e., plan members with diabetes whose blood sugar is under control) [10] . The implementation of the measure emphasizes the responsibility of health plans to monitor and improve glycemic control.
There is emerging interest in examining the influence of HbA1c variability in chronic complications of diabetes [11, 12] . Recent studies have found the development of microalbuminuria, progression of nephropathy, and incidence of cardiovascular disease related to HbA1c variability independent of the mean HbA1c level [12] [13] [14] . In people with type 2 diabetes, high levels of HbA1c, HbA1c variability, absolute changes in HbA1c might be associated with increased mortality [14] [15] [16] . However, HbA1c is not an independent predictor of antidiabetic medication nonadherence [17] . As far as we know, no published population-base studies on relationship of HbA1c variability and poor glycemic control. Therefore, we have investigated poor glycemic control and its relation to both HbA1c variability and absolute changes in HbA1c levels in older adults with diabetes enrolled in Medicare Advantage plans. We therefore aim
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Methods

Data source
The Independence Blue Cross (IBC) Active Enterprise Data Warehouse (AEDW) was utilized, consisting of an integrated dataset containing patient demographics, diagnosis, procedures, and detailed pharmacy information as well as laboratory data, including International Classification of Diseases, 9
th Revision, Clinical Modification (ICD-9-CM) codes; Current Procedural Terminology (CPT) and Healthcare Common Procedure Coding System (HCPCS) codes for each procedure, National Drug Codes (NDC) for drug dispensed, and Health Care Financing Administration (HCFA) codes for specialty. IBC serves nearly 10 million people in 27 states and the District of Columbia across the United States, including 2.5 million members in southeastern pennsylvania. This retrospective claims data analysis was conducted in compliance with state and federal laws, including the Health Insurance Portability and Accountability Act of 1996. All claims data were from a limited dataset with de-identified patient information. No patients were directly involved in the study; therefore, review by an institutional review board was unnecessary.
Inclusion/exclusion criteria
To define diabetes, we applied the Healthcare Effectiveness Data and Information Set (HEDIS) codes defined by the National Committee for Quality Assurance (NCQA) [18] . HEDIS defined diabetic patients in the Medicare Advantage plans as members with diabetes (type 1 or type 2) and no more than 1 gap in enrollment of up to 45 days during the MY. To determine continuous enrollment for a Medicare beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (i.e., a member whose coverage lapsesfor 2 months [60 days] is not considered as continuously enrolled). Two methods identify members with diabetes: pharmacy data and claims/encounter data. The organization must use both to identify the eligible population, but a member only needs to be identified in 1 to be included in the measure. Members may be identified as having diabetes during the MY or the year prior to the MY [19] . Our study sample consisted of patients with diabetes continuously enrolled in Medicare Advantage plans in IBC from 2013 to 2014 and had ≥ 3 HbA1c measurements in MY2013. We included patient aged 65 years or older. We excluded patients who did not have a diagnosis of diabetes and had a diagnosis of polycystic ovaries, gestational diabetes or steroid-induced diabetes [10] .
Data management
Poor glycemic control was identified as the most recent HbA1c level > 9.0% during the MY, per the CMS/NCQA definition [10, 18] . HbA1c was defined as within-subject standard deviation of HbA1c levels; absolute change in HbA1c was defined as the difference between the most recent HbA1c and the first HbA1c level measured in MY2013. We used patients' zip codes to link to 2010 US census to get socioeconomic status information. General health status was assessed through the Charlson comorbidity index [20] . The comorbidity index was assessed from claims data for services provided between January 1, 2013 and December 31, 2013; and each claim was billed at least one primary ICD-9 diagnosis code and up to 15 secondary diagnosis codes. The comorbidity index was assessed using the Deyo strategy [21] . The comorbidity index was modified and computed for all diagnoses recorded in all of the claims during the year excluding diabetes because all study subjects had this diagnosis. Comorbidities and complications were identified by ICD-9 diagnosis codes (primary or secondary) and included the following: diabetic retinopathy (362. anxiety (300.xx except 300.3 and 300.4), and depression (311; 296.2; 296.3; 296.5-296.7; 300.4 or 296.82; 296.89). DxCG risk score refers to the concurrent medical risk score calculated using the medical risk adjustment model developed by Verisk Health DxCG Risk solutions, version 3.1 (Verisk Health, Cary, NC) [22] . These models use linear, additive formulas obtained from ordinary least squares regressions to generate predictions from expenses associated with clinical data and demographic factors. The risk score employed here used patient age, gender, and claims information from all medical encounter and enrollment data to estimate annual total medical resource use [22] . We categorized the score as 1 (1 st tertile, low risk), 2 (2 nd tertile, middle), and 3 (3 rd tertile, high risk) in this study. The adherence to diabetic medication was defined by the medication possession ratio (MPR). The MPR is calculated as the sum of total days' supply of the medication from the first to the last prescription fill, divided by the total number of days in this period [23] . The MPR was calculated separately for each drug class for all diabetic medications prescribed for a subject using prescription medication claims data from AEDW. Then, an average MPR was calculated with equal weighting of each drug class. The average antidiabetic medication MPR was dichotomized as non adherent and adherent according to the traditional standard of < 80% and ≥ 80%, respectively [24] .
Statistical analysis
We first described the social demographic and clinical characteristics of the patients in this cohort by calculating percentages for categorical variables and media plus interquartile range for continuous variables. Patients were divided into five groups according to the HbA1c variability quintile. Comparisons of social demographic and clinical characteristics of each group were performed using the chi-square test for categorical variables and the one-way ANOVA test for continuous variables. Bivariate associations between covariates and poor glycemic control were tested using the chi-square test for categorical variables and the Wilcoxon rank-sum test for continuous variables. To assess the relationships between HbA1c variability or absolute change in HbA1c and poor glycemic control, we fitted univariate and multivariable logistic regression models. The multivariable regression model included covariates that were statistically significantly associated with poor glycemic controlbased on bivariate associations and variables deemed important to predicting poor glycemic control according to literature review. These variables contained age in years, gender, race, mean A1c, obesity, depression, chronic kidney disease, charlson comorbidity index, DxCG risk score, emergency department visit, number of outpatient visit, any hospitalization, number of PCP/internist visit, number of specialist visit, number of distinct generic drug use, and insulin use during MY2013. For all logistic regression models, the odds ratio (OR) and 95% confidence intervals (CIs) were calculated, and p < 0.05 (two tailed) was used for all significance levels. The Hosmer-Lemeshow test for goodness-of-fit was used to evaluate the models. All data management and statistical analyses were conducted using SAS 9.4 (SAS Institute Inc., Cary, NC).
Results
There were a total of 4,458 diabetes patients aged 65 years or older and continuously enrolled in Medicare Advantage plans in IBC from 2013 to 2014 with at least 3 HbA1c measurements in MY2013 ( Table  1) . The majority of patients were female (54.4%), the mean age was 78.3 years, 15% of patients with obesity, 86% with hyperlipidemia, 90% with hypertension, 15% with stroke, near 7% with anxiety, 8% with depression, 22% with chronic kidney disease. More than 30% of the patients had at least one emergency room visit. The average number of outpatient visits per patient was two, primary care or intern physician visit was six, and specialist visit was 4. The average number of distinct generic drugs used per patient was ten. More than 70% of the patients were adherent to antidiabetic medications, and 22.7% used insulin. The average within-subject mean HbA1c level was 7% ± 1.1%. Figure 1 shows the individual HbA1c level profile during the MY by HbA1c variability quintile. The group of highest HbA1c variability quintile had the biggest variation across HbA1c measurements within subjects, while the group of lowest HbA1c variability quintile had the smallest variation over HbA1c measurements within subjects. Figure  2 demonstrates the changes in the HbA1c level in the five groups with different HbA1c variability over the MY, illustrating relative stable in average HbA1c lever across measurements in each group. The group of highest HbA1c variability quintile had the highest HbA1c level, while the group of lowest HbA1c variability quintile had the lowest HbA1c level over measurements. Table 1 also shows that increasing quintiles of HbA1c variability are associated with increased mean HbA1c (p < 0.0001). Table 1 shows the social demographic and clinical characteristics of the five groups with different HbA1c variabilities. There were no differences in race, median household income, and education level, plan type (HMO [health maintenance organization] or PPO [preferred provider organization]), or adherent to antidiabetic medications among the groups. However, as the HbA1c variability increased, mean age decreased significantly. The rates of obesity, tobacco use, ischemic heart disease, depression, chronic kidney disease, diabetic complications, modified charlson comorbidity index, DxCG risk score, insulin use, number of distinct generic drug used, and other medical services utilization increased significantly with the increasing quintile of HbA1c variability. As the HbA1c variability increased, the number of HbA1c measurements, mean HbA1c, absolute changes in HbA1c, and the rate of poor glycemic control increase significantly. The HbA1c variability was also closely related to the mean HbA1c of all patients (r = 0.576, p < 0.0001).
A total of 21.9% (95% CI: 20.67-23.11) of patients had poor glycemic control in MY2014 in this study cohort. Obesity, depression, * data presented as median (interquartile range) ** MPR, medication possession ratio was averaged across medication classes for subjects taking medications from more than 1 drug class. Non adherence was defined as MPR < 80%. chronic kidney disease, insulin use, emergency department visits, higher number of outpatient visits, any hospitalization, higher within-subject mean and within-subject absolute change HbA1c were significantly associated with poor glycemic control ( Table 2) . No significant associations were found for all other factors such as age, gender, race, household income, education level, tobacco use, hypertension, ischemic heart disease, anxiety, diabetic complications, Charlson comorbidity index and DxCG risk score.
The proportion of patients who had poor glycemic control increased overall with increasing quintiles of HbA1c variability (15.4%, 15.9%, 18.1%, 22.1%, 28.5%, p < 0.0001 for association; Table 2 ). In the unadjusted logistic regression model, there was a moderately strong association between HbA1c variability and poor glycemic control that was statistically significant for the highest quintile (OR = 2.52, 95% CI = 1.91-3.34; Table 3 ). However, the fully adjusted model showed no association between HbA1c variability and poor glycemic control. Poor glycemic control was significantly associated with mean HbA1c level (OR = 1.70, 95% CI = 1.52-1.90), absolute change in HbA1c level (OR = 1.14, 95% CI = 1.03-1.26), chronic kidney disease (OR = 1.42, 95% CI = 1.08-1.86), number of primary care visits (OR = 0.98, 95% CI = 0.97-0.99), number of specialist visits (OR = 1.02, 95% CI = 1.01-1.04), and insulin use (OR = 1.36, 95% CI = 1.05-1.78). All other independent variables (age, gender, obesity, depression, Charlson comorbidity index, DxCG risk score, emergency department visits, number of outpatient visits, hospitalization, and number of distinct generic drug used) were not significantly associated with poor glycemic control in this study population (all p > 0.05, Table 3 ).
Discussion
We found that HbA1c variability was not an independent predictor of poor glycemic control in a population aged 65 years or older with diabetes in Medicare Advantage plans. However, mean HbA1c, absolute change in HbA1c level, number of primary care visits, number of specialist visits, and insulin use were statistically significantly associated with poor glycemic control.
Although diabetes care has been improved over time, the magnitude of poor glycemic control in older diabetic patients is high [7, 8] . For instance, a study conducted in older Mexican American diabetics aged ≥ 75 years showed 65.1% had HbA1c > 7.0% [25] , and 38.4% Malaysian patients aged ≥ 60 years had HbA1c ≥ 8.0% [26] . We found nearly 22% of older adults aged ≥ 65 years with diabetes had poor glycemic control (HbA1c ≤ 9.0%), suggesting that there is room to improve diabetes outcomes. Moreover, different researchers have shown that poor glycemic control of diabetic patients leads to microvascular and macrovascular complications. However, lowering HbA1 concentrations significantly reduces the rate of progression of microvascular complications. A group-level meta-analysis of ACCORD, ADVANCE, and VADT suggested that glucose lowering had a modest (9%) but statistically significant reduction in major cardiovascular disease, primarily nonfatal myocardial infarction outcomes [5] .
There are potentially many factors behind the challenges in glycemic control investigation. Healthcare claims databases do not contain some robust information such as body mass index (BMI), blood pressure, and stress management. Robust evidence may require high quality long-term prospective study or randomized cohort data. Recently several studies have examined socio-demographic, behavioral, and treatment related factors behind glycemic control and generated new insights on the potential factors of glycemic outcomes [25] [26] [27] [28] [29] .
A unique strength of our study was the ability to assess longitudinal HbA1c profile and comprehensive characteristics of patients and link these characteristics to glycemic control in a large retrospective cohort design. To our knowledge, ours is the first such study. We found that the proportion of patients who had poor glycemic control increased with increasing quintiles of HbA1c variability and increasing quintiles of HbA1c variability are associated with both increased mean HbA1c and absolute change in HbA1c. Similar to the other study on HbA1c variability and adherence to antidiabetic medications [17] , we didn't find significant association between HbA1c variability and poor glycemic control in the full adjusted model. This could have been the result of the correlation of mean HbA1c and HbA1c variability.
In the univariate analysis, there was a moderately strong association between HbA1c variability and poor glycemic control. However, no association was found after adjustment by mean HbA1c and other co-variables. Mean HbA1c was the most significant predictor and absolute change in HbA1c was marginally associated with poor glycemic control.
In this study, patients who visited their primary care physicians (PCPs) more frequently or visited their specialists less were less likely to have poor glycemic control. More specialist visits may indicate that the diabetes is more severe and/or patients are more complex with multiple comorbidities. The patients who visited their PCPs more often may have the opportunity for more intensive monitoring of their HbA1c. PCPs might have been more able to focus on a patient's diabetes management because other medical problems were being addressed by specialist providers. Similar to other reports, we found that patients who received insulin treatment [30, 31] or with chronic kidney disease [32] had higher likelihood of poor glycemic control.
Additional factors associated with poor glycemic control in older adults, including longer duration of diabetes [30, 31] , lower education level [25, 30] , ethnic variation [25, 33] , and lower physical activity [31, 34] , were not measured in this study. We did include specific diagnoses that often co-occur with diabetes, or that may affect glycemic control, such as obesity, hypertension, hyperlipidemia, stroke, anxiety, depression, ischemic heart disease, and diabetes related complications, such as retinopathy, neuropathy, and nephropathy in this study. We found that all these diseases were not associated with poor glycemic control; some of these results are inconsistent with previous research that showed that obesity [29] , depression [35] , anxiety [36] , diabetic retinopathy [29] , diabetic neuropathy [25, 29] , and diabetic nephropathy [29] are associated with poor glycemic control.
Limitations
Our study had several limitations. First, this study is a retrospective observational study, and we do not know the reasons for having HbA1c measured or the reasons behind the changes in HbA1c. Most likely, the previously measured HbA1c level and the clinical conditions of the patient will have been influenced when a new measurement was made. Those who did not have a measurement in MY2013 or those who did not have at least 3 measurements have been excluded in this cohort. Second, the healthcare claims database that was analyzed had no information of diabetic duration, severity of disease, and lifestyles, such as diet, exercise and drinking habits, which may influence outcomes. Third, we obtained household income and education level from US census data at a zipcode level. This data may be not accurate at an individual level. Fourth, our study cohort consists of Medicare beneficiaries at a single managed health care system; although the sample size is relative big, the findings may not apply to other setting. Fifth, the use of ICD-9 diagnosis codes is not as rigorous as formal clinical assessments and may underrepresent certain conditions. Finally, the analyses may not have captured all variables as previously discussed that may potentially impact glycemic control.
Conclusion
This real-world retrospective study has shown that the rate of poor glycemic control among older adults with diabetes is still high and HbA1c variability is not a robust indicator of poor glycemic control; however, mean HbA1c, absolute change in HbA1c level, number of primary care visits, number of specialist visits, and insulin use are significantly associated with poor glycemic control. Further studies are needed to explore this finding and to determine the association of other variables with glycemic control. Future research should use all available information to develop a reliable predictive tool to identify at-risk patients and deliver appropriate interventions to target population.
